GlaxoSmithKline Stock News

Glaxosmithkline plc - ADR (GSK) shares closed 2.5% higher than its previous 52 week high, giving the company a market cap of $114B. The stock is currently up 3.1% year-to-date, up 25.0% over the past 12 months, and up 50.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 7.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 20.2% The company's stock price performance over the past 12 months lags the peer average by -21.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.9% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Stock Futures Slump As Bond Yields, Oil Prices Leap; Week Ahead: Earnings in Focus After Mixed Q4 Start; Airlines Warn On 5G Disruption After Another Chaotic Weekend For Flights; Activision Blizzard Confirms Firings in Sexual Harassment Probe and GlaxoSmithKline Rejects $68 Billion Unilever Bid For Consumer Goods Division.

Unilever Plc (UL) is facing investor backlash over its £50B ($68B) offer for GlaxoSmithKline''s (GSK) consumer business

Unilever shares slumped Monday as the consumer products giant suggested it might increase its offer for GlaxoSmithKline''s consumer health unit.

Unilever Plc (UL) has negotiated with banks about securing additional financing for a sweetened offer for the consumer unit of GlaxoSmithKline (GSK), Bloomberg reported on Sunday,

(Reuters) Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plcs consumer products division, Bloomberg reported on Sunday, citing people familiar with the matter.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.4% below its 52 week high of $45.67, giving the company a market cap of $114B. The stock is currently up 3.1% year-to-date, up 26.0% over the past 12 months, and up 50.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 3.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 20.2% The company's stock price performance over the past 12 months lags the peer average by -17.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.9% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

GlaxoSmithKline rejects three purchase offers from Unilever for its Consumer Healthcare business. The U.K. pharma giant says the business is well-positioned to sustainably grow ahead of its categories in the years to come. GSK plans to create a new independent consumer company, which is on track to be achieved by mid-2022. U.K. pharma giant GlaxoSmithKline plc (NYSE: GSK ) has spurned multiple offers for its Consumer Healthcare business on the grounds that the offers undervalued the unit. GlaxoSmithKline said in a statement Saturday that Unilever plc (NYSE: UL ) tabled three unsolicited, conditional and non-binding proposals for acquiring its Consumer Healthcare Full story available on Benzinga.com

GlaxoSmithKline (GSK) said it rejected three non-binding offers from Unilever Plc (UL) for its consumer healthcare business, including its latest bid of 50B pounds ("$68B") in cash

The pharmaceutical giant GlaxoSmithKline says it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit

Glaxosmithkline plc - ADR (GSK) shares closed 0.1% higher than its previous 52 week high, giving the company a market cap of $113B. The stock is currently up 2.2% year-to-date, up 26.5% over the past 12 months, and up 49.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 0.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 22.5% The company's stock price performance over the past 12 months lags the peer average by -16.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -34.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

An expert panel at the World Health Organization ((WHO)) recommended the use of two treatments developed by Eli Lilly (LLY) and GlaxoSmithKline (GSK)/Vir Biotechnology (VIR) for

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) announced the submission to the FDA of an application seeking an amendment to the Emergency Use Authorization ((EUA)) for sotrovimab…